LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

ABBV

194.81

+0.93%↑

MRK

110.27

+1.63%↑

LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

ABBV

194.81

+0.93%↑

MRK

110.27

+1.63%↑

LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

ABBV

194.81

+0.93%↑

MRK

110.27

+1.63%↑

LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

ABBV

194.81

+0.93%↑

MRK

110.27

+1.63%↑

LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

ABBV

194.81

+0.93%↑

MRK

110.27

+1.63%↑

Home・Stock List・Johnson and Johnson

Johnson and Johnson

Closed

Sector Healthcare

160.83 0.76

Buy Sell

Overview

Share price change

24h

Current

Min

159.5

Max

161.2

Key metrics
By Trading Economics
Income	1.4B 4.7B
Sales	1.1B 22B
P/E Sector Avg	21.72 113.916
EPS	2.82
Profit margin	20.873
Employees	131,900
EBITDA	2.1B 7.8B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+8.38 upside

Dividends
By Dow Jones
Next Earnings	15 Oct 2024
Next Dividend date	3 Dec 2024
Next Ex Dividend date	18 Nov 2024

Market Stats
By TradingEconomics
Market Cap	265M 389B
Previous open	160.07
Previous close	160.83

News Sentiment

By Acuity

23%

77%

57 / 366 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

159.22 / 160.36 Support & Resistance

Johnson and Johnson Chart

Past performance is not a reliable indicator of future results.

Related News

20 Aug 2024, 12:16 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Buy V-Wave for Upfront Payment of $600 Million

20 Aug 2024, 11:43 UTC

Top News

Johnson & Johnson's Rybrevant, Lazcluze Combo Gets FDA Approval for Type of Advanced Lung Cancer

17 Jul 2024, 14:14 UTC

Earnings

Trending: Johnson & Johnson Beats 2Q Sales Guidance

20 Sept 2024, 21:58 UTC

Top News

Johnson & Johnson Files Third Bankruptcy Case Seeking to End Talc Lawsuits -- 3rd Update

20 Sept 2024, 21:28 UTC

Top News

Johnson & Johnson Files Third Bankruptcy Case Seeking to End Talc Lawsuits -- 2nd Update

20 Sept 2024, 20:06 UTC

Top News

Johnson & Johnson Files Third Bankruptcy Case Seeking to End Talc Lawsuits -- Update

20 Sept 2024, 19:58 UTC

Top News

Johnson & Johnson Files Third Bankruptcy Case Seeking to End Talc Lawsuits -- WSJ

4 Sept 2024, 23:20 UTC

Top News

Johnson & Johnson Wins Over Longtime Holdout for Talc Settlement -- Update

23 Aug 2024, 20:54 UTC

Top News

J&J Takes Aim at Hospital Drug-Discount Program -- Update

23 Aug 2024, 18:09 UTC

Top News

J&J Takes Aim At Hospital Drug-Discount Program -- WSJ

20 Aug 2024, 12:41 UTC

Top News

Acquisitions, Mergers, Takeovers

Johnson & Johnson Gets FDA Approval for Treatment, Makes Acquisition of Up to $1.7 Billion -- Barrons.com

20 Aug 2024, 12:01 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Buy V-Wave for Upfront Payment of $600M

20 Aug 2024, 11:55 UTC

Acquisitions, Mergers, Takeovers

J&J To Acquire V-Wave For Up To $1.7 Billion In Play For Heart Failure Device -- MarketWatch

20 Aug 2024, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Expects the Transaction to Dilute Adjusted EPS by 24c in 2024 and 6c in 2025 >JNJ

20 Aug 2024, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Transaction Is Expected to Close Before the End of 2024 >JNJ

20 Aug 2024, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Will Join Johnson & Johnson as Part of Johnson & Johnson MedTech >JNJ

20 Aug 2024, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Will Acquire V-Wave for an Upfront Payment of $600M With the Potential for Additional Regulatory and Comml Milestone Payments Up to $1.1B >JNJ

20 Aug 2024, 11:30 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson To Acquire V-Wave >JNJ

20 Aug 2024, 11:12 UTC

Top News

Johnson & Johnson Wins First FDA Approval For Chemotherapy-Free Lung Cancer Treatment -- MarketWatch

12 Aug 2024, 14:30 UTC

Acquisitions, Mergers, Takeovers

Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ

12 Aug 2024, 09:30 UTC

Top News

Acquisitions, Mergers, Takeovers

Big Drugmakers Are Clinching Smaller Deals -- WSJ

29 Jul 2024, 10:30 UTC

Top News

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

17 Jul 2024, 11:24 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

J&J Lifts Sales View But Lowers Earnings Outlook -- Market Talk

17 Jul 2024, 10:43 UTC

Earnings

Johnson & Johnson Earnings Top, But Dow Stock Falls On Lowered Guidance -- IBD

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson: MedTech Operational Sales Growth Expected to Accelerate in 2H >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson Cuts 2024 View To Adj EPS $9.97-Adj EPS $10.07 Vs Prior View $10.57-$10.72 >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson Backs 2024 Adjusted Operational Sales Growth View of 5.5%-6% >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson: 2Q MedTech Worldwide Operational Sales Growth Was Driven Primarily by Electrophysiology Products and Abiomed in Cardiovascular, and Wound Closure Products in General Surgery >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson Backs 2024 Sales $88.0B-$88.4B >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson Cuts 2024 Adjusted Operational EPS View to $10.00-$10.10 Vs Prior View $10.60-$10.75 >JNJ

Peer Comparison

Price change

Johnson and Johnson Forecast

Price Target

By TipRanks

8.38% upside

12 Months Forecast

Average 173.08 USD 8.38%

High 215 USD

Low 150 USD

Based on 15 Wall Street analysts offering 12 month price targets forJohnson and Johnson - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

15 ratings

Buy

Hold

Sell

Based on 15 analysts giving stock ratings to Johnson and Johnson - Dist in the past 3 months.

Technical Score

By Trading Central

159.22 / 160.36Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

57 / 366 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Johnson and Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.